WELCOME TO PARI PHARMA!

The future of effective aerosol therapies lies in the optimization of drug-to-device and device-to-drug. PARI Pharma has taken the next step and combined formulation development, next generation aerosol platforms, and aerosol characterization under one roof.

We are currently working with both the eFlow Technology (lower respiratory) and Vibrent Technology (upper respiratory) Advanced Aerosol Delivery platforms.

This multifunctional development program is the key to creating targeted therapies with high deposition amounts, low side-effect profiles, improved patient compliance…and better controlled, healthier patients.

After 100 years, we know aerosol science and aerosol delivery.

Tuesday, 13. November 2012

Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE

Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target...
Thursday, 30. August 2012

Sunovion Pharmaceuticals Inc. to Acquire Elevation Pharmaceuticals, Inc.

 

Marlborough, Mass., August 30, 2012 – Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has signed a definitive agreement (“Agreement”)...

 

Wednesday, 30. May 2012

INSMED PROVIDES CORPORATE UPDATE

 

- Company Sets Current ARIKACE Development Priorities  -

- Insmed Projects Cash Sufficient to Generate Top-Line Data from Three Priority Studies  -...

 

Monday, 07. May 2012

INSMED INCORPORATED ANNOUNCES LIFTING OF CLINICAL HOLD BY U.S. FOOD AND DRUG ADMINISTRATION ON ARIKACE® IN CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS LUNG INFECTIONS

 

Monmouth Junction, N.J. – May 7, 2012 - Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and...

 

Friday, 10. February 2012

INSMED INCORPORATED PROVIDES UPDATE ON CLINICAL PROGRAM FOR ARIKACE

 

Monmouth Junction, N.J. – February 10, 2012 - Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company is...